Piper Sandler raised the firm’s price target on Inspire Medical to $360 from $340 and keeps an Overweight rating on the shares. The analyst continues to view Inspire as a “high-conviction name” and sees the potential for meaningful numbers upside to play out through 2025. The U.S. obstructive sleep apnea market is very large and growing, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on INSP:
- Inspire Medical price target raised to $380 from $300 at Mizuho
- Inspire Medical price target raised to $350 from $300 at Stifel
- Inspire Medical Systems, Inc. to Report Second Quarter 2023 Financial Results on August 1, 2023
- Inspire Medical price target raised to $355 from $310 at BofA
- Inspire Medical Systems, Inc. Announces FDA Approval for Apnea Hypopnea Index Indication Expansion and Increased Body Mass Index Labeling